Serina Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Serina Therapeutics, Inc. (SER) reported Increase (Decrease) in Accounts Payable of -$71.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Serina Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$967.00K, a 285.25% decline year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $896.00K, a 103.17% increase year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$811.00K.
- Serina Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $1.04M, a 112.40% increase year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $1.20M.
- Serina Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$1.66M, a 522.65% decline from fiscal 2023.
- Serina Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $393.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$967.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$71.00K 10-Q · filed 2026-08-13 | -$882.00K derived: sum of 3 quarters · filed 2026-08-13 | $163.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $896.00K 10-Q · filed 2026-05-14 | $85.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.13M derived: sum of 3 quarters · filed 2026-05-14 | $1.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$811.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $234.00K derived: sum of 2 quarters · filed 2026-03-25 | $756.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.20M 10-K · filed 2026-03-25 |
| 2025-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.57M derived: sum of 2 quarters · filed 2026-08-13 | $2.01M 10-Q · filed 2025-11-13 | $1.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $522.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $963.00K 10-Q · filed 2026-08-13 | $14.00K derived: sum of 3 quarters · filed 2026-08-13 | $506.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $441.00K 10-Q · filed 2026-05-14 | -$508.00K derived: sum of 2 quarters · filed 2026-05-14 | -$16.00K derived: sum of 3 quarters · filed 2026-05-14 | -$1.46M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$949.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$457.00K derived: sum of 2 quarters · filed 2026-03-25 | -$1.91M derived: sum of 3 quarters · filed 2026-03-25 | -$1.66M 10-K · filed 2026-03-25 |
| 2024-09-30 | $492.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$956.00K derived: sum of 2 quarters · filed 2025-11-13 | -$712.00K 10-Q · filed 2025-11-13 | -$842.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$1.20M 10-Q · filed 2025-08-11 | -$1.33M derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $244.00K 10-Q · filed 2025-05-08 | $114.00K derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | -$130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $393.00K 10-K · filed 2025-03-24 | ||
| 2023-09-30 | $523.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |